Clinical TrialMay 27, 2026, 02:31 AM
Aligos Therapeutics: Pevifoscorvir sodium shows cccDNA reduction, HBsAg eligibility
AI Summary
Aligos Therapeutics announced positive data from ten presentations at the European Association for the Study of the Liver (EASL) Congress 2026. Long-term follow-up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoir. Notably, 40% of HBeAg+ participants treated with pevifoscorvir sodium achieved HBsAg reductions that could qualify them for functional cure therapy. Additionally, preclinical data showed additive to synergistic effects when pevifoscorvir sodium was combined with the antisense oligonucleotide ALG-170675.
Key Highlights
- Pevifoscorvir sodium Phase 1 data suggests continued reduction in the cccDNA reservoir.
- 40% of HBeAg+ participants achieved HBsAg <3,000 IU/mL at 48 weeks, potentially qualifying for ASO treatment.
- Combination of pevifoscorvir sodium and ASO ALG-170675 showed additive to synergistic effects on HBV viral markers.
- 44% (4/9) of HBeAg+ subjects maintained HBV DNA levels below LLOQ during NA-only follow-up.
- Preclinical data on the Aligos/Amoytop ASO program was presented.
- Preclinical HDV program data demonstrated a novel approach to targeting HDV replication.
Price Impact
More from ALGS